1
40
42
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/ciy866" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/ciy866</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2018
2018-12
Creator
An entity primarily responsible for making the resource
Uyeki Timothy M; Bernstein Henry H; Bradley John S; Englund Janet A; File Thomas M Jr; Fry Alicia M; Gravenstein Stefan; Hayden Frederick G; Harper Scott A; Hirshon Jon Mark; Ison Michael G; Johnston B Lynn; Knight Shandra L; McGeer Allison; Riley Laura E; Wolfe Cameron R; Alexander Paul E; Pavia Andrew T
Description
An account of the resource
These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza pandemic. This document addresses new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza. It is intended for use by primary care clinicians, obstetricians, emergency medicine providers, hospitalists, laboratorians, and infectious disease specialists, as well as other clinicians managing patients with suspected or laboratory-confirmed influenza. The guidelines consider the care of children and adults, including special populations such as pregnant and postpartum women and immunocompromised patients.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/ciy866" target="_blank" rel="noreferrer noopener">10.1093/cid/ciy866</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2018
Alexander Paul E
Bernstein Henry H
Bradley John S
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Department of Family & Community Medicine
Department of Internal Medicine
Englund Janet A
File Thomas M Jr
Fry Alicia M
Gravenstein Stefan
Harper Scott A
Hayden Frederick G
Hirshon Jon Mark
Ison Michael G
Johnston B Lynn
Knight Shandra L
McGeer Allison
NEOMED College of Medicine
Pavia Andrew T
Riley Laura E
Uyeki Timothy M
Wolfe Cameron R
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.2146/ajhp130118" target="_blank" rel="noreferrer noopener">http://doi.org/10.2146/ajhp130118</a>
Pages
1908–1912
Issue
21
Volume
70
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Evaluation and use of a rapid Staphylococcus aureus assay by an antimicrobial stewardship program.
Publisher
An entity responsible for making the resource available
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Date
A point or period of time associated with an event in the lifecycle of the resource
2013
2013-11
Subject
The topic of the resource
Humans; Time Factors; Microbial Sensitivity Tests; Sensitivity and Specificity; Prospective Studies; Hospitals; Anti-Bacterial Agents/administration & dosage/*pharmacology; Bacteriological Techniques; False Negative Reactions; Methicillin-Resistant Staphylococcus aureus/*isolation & purification; Staphylococcal Infections/*diagnosis/microbiology; Staphylococcus aureus/*isolation & purification; Cell Culture Techniques; Chromatography; Human; Funding Source; Community; Affinity; Observational Methods; Biological Assay – Methods; Methicillin-Resistant Staphylococcus Aureus – Analysis
Creator
An entity primarily responsible for making the resource
Trienski Tamara L; Barrett Heather L; Pasquale Timothy R; DiPersio Joseph R; File Thomas M Jr
Description
An account of the resource
PURPOSE: The performance of a rapid test for methicillin-resistant Staphylococcus aureus (MRSA) in a large community hospital was investigated. METHODS: A prospective observational study was conducted to evaluate an immunochromatographic assay (Alere PBP2a Culture Colony Test, Alere Scarborough, Inc.) for rapid differentiation of MRSA and methicillin-susceptible S. aureus (MSSA) strains using isolates cultured overnight on common laboratory media. S. aureus isolates cultured for 12-24 hours were tested with the assay, which detects penicillin-binding protein 2a (PBP2a) and provides results in six minutes. The test results were compared with data from standard overnight antimicrobial susceptibility testing to determine the assay's sensitivity and specificity. Changes in therapy associated with use of the rapid assay were evaluated. RESULTS: Over an 11-month period, 661 inpatient isolates from mostly nonhematologic sites were tested. There were six false-negative results, indicating assay sensitivity of 98.4%, with no false positives (specificity of 100%). Eight invalid test results were documented. During designated evaluation periods, a total of 169 patient cases involving PBP2a testing were reviewed by the hospital's antimicrobial stewardship pharmacist. In 63 of those cases (37%), changes in therapy were implemented on the day of test result posting. Interventions often involved switching patients from inappropriate to appropriate MRSA therapy or optimizing MRSA- or MSSA-targeted therapy. CONCLUSION: An assay for quickly differentiating between MRSA and MSSA was highly sensitive, highly specific, and inexpensive in actual hospital use and led to rapid prescription of appropriate antistaphylococcal therapy 24-48 hours after culture specimens were collected.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2146/ajhp130118" target="_blank" rel="noreferrer noopener">10.2146/ajhp130118</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2013
Affinity
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Anti-Bacterial Agents/administration & dosage/*pharmacology
Bacteriological Techniques
Barrett Heather L
Biological Assay – Methods
Cell Culture Techniques
Chromatography
Community
Department of Internal Medicine
DiPersio Joseph R
False Negative Reactions
File Thomas M Jr
Funding Source
Hospitals
Human
Humans
Methicillin-Resistant Staphylococcus Aureus – Analysis
Methicillin-Resistant Staphylococcus aureus/*isolation & purification
Microbial Sensitivity Tests
NEOMED College of Medicine
Observational Methods
Pasquale Timothy R
Prospective Studies
Sensitivity and Specificity
Staphylococcal Infections/*diagnosis/microbiology
Staphylococcus aureus/*isolation & purification
Time Factors
Trienski Tamara L
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1007/bf03256666" target="_blank" rel="noreferrer noopener">http://doi.org/10.1007/bf03256666</a>
Pages
385–394
Issue
5
Volume
2
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Management of community-acquired pneumonia: a focus on conversion from hospital to the ambulatory setting.
Publisher
An entity responsible for making the resource available
American journal of respiratory medicine : drugs, devices, and other interventions
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
1905-06
Subject
The topic of the resource
*Ambulatory Care; *Hospitalization; Anti-Bacterial Agents/*administration & dosage; Bacterial/*therapy; Community-Acquired Infections/therapy; Humans; Pneumonia
Creator
An entity primarily responsible for making the resource
Tan James S; File Thomas M Jr
Description
An account of the resource
Patients with community-acquired pneumonia (CAP) are treated in hospital or in the ambulatory care setting depending on the severity of illness. Despite numerous guidelines proposed, there is no agreement on specific criteria for hospitalization other than the clinicians' experience. The purpose of this review is to discuss the importance of the appropriate choice and timely administration of antibacterial agents, either in the hospital or in the outpatient setting. Since a high proportion of CAP patients will not have an etiologic agent identified at the time of initiation of treatment, the choice of antibacterial therapy is usually empiric. Antibacterial agents with activity against pneumococci and atypical pathogens causing pneumonia are the preferred choices. Macrolides, doxycycline, or respiratory fluoroquinolones have been recommended by various guidelines committees in North America for the treatment of pneumonia in patients with or without underlying comorbidities. Because of the increasing resistance to beta-lactams as well other antibacterial agents such as macrolides, doxycycline, and sulfamethoxazole/trimethoprim (cotrimoxazole), it is important that clinicians are aware of local statistics on resistance to Streptococcus pneumoniae, as infection with this bacterium is associated with high rates of morbidity and mortality. More recently, fluoroquinolone resistance has been reported, but the percentage of pneumococcal strains resistant to this agent is relatively low compared with the other antibacterial agents. Switch (intravenous to oral) therapy is recommended for hospitalized patients with CAP to facilitate early discharge, which has been shown to improve patient satisfaction and reduce hospital costs. Early conversion to oral therapy has not been shown to be associated with increased complications or higher mortality. Following prompt intravenous therapy and stabilization, patients with CAP should be treated with oral therapy in the ambulatory setting.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1007/bf03256666" target="_blank" rel="noreferrer noopener">10.1007/bf03256666</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Ambulatory Care
*Hospitalization
2003
American journal of respiratory medicine : drugs, devices, and other interventions
Anti-Bacterial Agents/*administration & dosage
Bacterial/*therapy
Community-Acquired Infections/therapy
Department of Internal Medicine
File Thomas M Jr
Humans
NEOMED College of Medicine
Pneumonia
Tan James S
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.cger.2016.02.012" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.cger.2016.02.012</a>
Pages
459–477
Issue
3
Volume
32
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Bacterial Pneumonia in Older Adults.
Publisher
An entity responsible for making the resource available
Clinics in geriatric medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
2016-08
Subject
The topic of the resource
*Community-acquired; *Decision Making; *Elderly; *Etiology; *Pneumonia; *Risk factors; *Treatment; Aged; Bacterial – Epidemiology; Bacterial/*epidemiology; Community-Acquired Infections – Epidemiology; Community-Acquired Infections/*epidemiology; Decision Making; Global Health; Humans; Incidence; Pneumonia; Risk Factors; World Health
Creator
An entity primarily responsible for making the resource
Marrie Thomas J; File Thomas M Jr
Description
An account of the resource
Community-acquired pneumonia is common in the elderly person; its presentation in this population is often confounded by multiple comorbid illnesses, including those that result in confusion. Although severity-of-illness scoring systems might aid decision-making, clinical judgment following a careful assessment is key in deciding on the site of care and appropriate therapy.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.cger.2016.02.012" target="_blank" rel="noreferrer noopener">10.1016/j.cger.2016.02.012</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Community-acquired
*Decision Making
*Elderly
*Etiology
*Pneumonia
*Risk factors
*Treatment
2016
Aged
Bacterial – Epidemiology
Bacterial/*epidemiology
Clinics in geriatric medicine
Community-Acquired Infections – Epidemiology
Community-Acquired Infections/*epidemiology
Decision Making
Department of Internal Medicine
File Thomas M Jr
Global Health
Humans
Incidence
Marrie Thomas J
NEOMED College of Medicine
Pneumonia
Risk Factors
World Health
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/cix531" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/cix531</a>
Pages
1596–1596
Issue
9
Volume
65
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Reply to Bush and Kaye.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
2017-10
Creator
An entity primarily responsible for making the resource
Kullar Ravina; Goff Debra A; Bauer Karri A; File Thomas M Jr
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/cix531" target="_blank" rel="noreferrer noopener">10.1093/cid/cix531</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2017
Bauer Karri A
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Department of Internal Medicine
File Thomas M Jr
Goff Debra A
Kullar Ravina
NEOMED College of Medicine
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/ciw247" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/ciw247</a>
Pages
532–538
Issue
4
Volume
63
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Approaches to Modifying the Behavior of Clinicians Who Are Noncompliant With Antimicrobial Stewardship Program Guidelines.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
2016-08
Subject
The topic of the resource
*antibiotic stewardship; *Antimicrobial Stewardship; *ASP; *outlier physicians; *peer review; *Practice Patterns; Anti-Bacterial Agents/*therapeutic use; Communication; Evidence-Based Medicine; Guideline Adherence; Humans; Physicians; Physicians'; Practice Guidelines as Topic
Creator
An entity primarily responsible for making the resource
Goldstein Ellie J C; Goff Debra A; Reeve William; Naumovski Snezana; Epson Erin; Zenilman Jonathan; Kaye Keith S; File Thomas M Jr
Description
An account of the resource
Antimicrobial stewardship programs (ASPs) are a key national initiative to promote appropriate use of antibiotics and to reduce the burden of resistance. The dilemma of managing the outlier physician is especially complex. We outline strategies to establish a successful ASP that reviews appropriate efforts to achieve the goal of modifying outlier physicians' behavior. One must try to differentiate deviation from ASP norms from all other issues of outliers. Essential elements include identifying and understanding the local problems, planning, and achieving hospital administration and medical staff support. A successful ASP includes effective communication and acceptance of evidence-based recommendations, so that patient clinical outcomes will be optimized.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/ciw247" target="_blank" rel="noreferrer noopener">10.1093/cid/ciw247</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*antibiotic stewardship
*Antimicrobial stewardship
*ASP
*outlier physicians
*peer review
*Practice Patterns
2016
Anti-Bacterial Agents/*therapeutic use
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Communication
Department of Internal Medicine
Epson Erin
Evidence-Based Medicine
File Thomas M Jr
Goff Debra A
Goldstein Ellie J C
Guideline Adherence
Humans
Kaye Keith S
Naumovski Snezana
NEOMED College of Medicine
Physicians
Physicians'
Practice Guidelines as Topic
Reeve William
Zenilman Jonathan
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.idc.2016.02.012" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.idc.2016.02.012</a>
Pages
539–551
Issue
2
Volume
30
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The Evolving Role of Antimicrobial Stewardship in Management of Multidrug Resistant Infections.
Publisher
An entity responsible for making the resource available
Infectious disease clinics of North America
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
2016-06
Subject
The topic of the resource
*Anti-Bacterial Agents/administration & dosage/therapeutic use; *Antibiotics; *Antimicrobial resistance; *Antimicrobial stewardship; *Drug Resistance; *Medication Therapy Management; Bacterial; Bacterial Infections/drug therapy; Humans; Multiple
Creator
An entity primarily responsible for making the resource
Goff Debra A; File Thomas M Jr
Description
An account of the resource
This article summarizes the current literature describing how antimicrobial stewardship interventions impact antimicrobial resistance. Discussion includes why we need stewardship, how to collaborate with team members, and the evidence of stewardship's impact on resistance.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.idc.2016.02.012" target="_blank" rel="noreferrer noopener">10.1016/j.idc.2016.02.012</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Anti-Bacterial Agents/administration & dosage/therapeutic use
*Antibiotics
*Antimicrobial resistance
*Antimicrobial stewardship
*Drug Resistance
*Medication Therapy Management
2016
Bacterial
Bacterial Infections/drug therapy
Department of Internal Medicine
File Thomas M Jr
Goff Debra A
Humans
Infectious disease clinics of North America
Multiple
NEOMED College of Medicine
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1097/IPC.0000000000000350" target="_blank" rel="noreferrer noopener">http://doi.org/10.1097/IPC.0000000000000350</a>
Pages
3–10
Issue
1
Volume
24
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Diagnosis and Treatment of Clostridium difficile Infection (CDI).
Publisher
An entity responsible for making the resource available
Infectious diseases in clinical practice (Baltimore, Md.)
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
2016-01
Subject
The topic of the resource
CDI; Clostridium difficile; diagnostic test; treatment
Creator
An entity primarily responsible for making the resource
Gerding Dale N; File Thomas M Jr; McDonald L Clifford
Description
An account of the resource
Early and accurate diagnosis is essential for optimal treatment of individuals with Clostridium difficile infection (CDI) and for implementation of effective infection control procedures. The decision about which diagnostic test to use is an important one that should be based on test sensitivity, specificity, and predictive value. The challenges of CDI go beyond rapid identification and management of symptomatic patients. Asymptomatic carriage has long been suspected in C. difficile transmission, but it may play a larger role than previously thought. Emerging information also shows that patients treated for CDI remain colonized for many weeks after symptom resolution. In fact, stool culture positivity increases during the first weeks following treatment completion. Treatments that reduce the duration and degree of asymptomatic shedding could have added benefit for reduced transmission.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1097/IPC.0000000000000350" target="_blank" rel="noreferrer noopener">10.1097/IPC.0000000000000350</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2016
CDI
Clostridium difficile
Department of Internal Medicine
diagnostic test
File Thomas M Jr
Gerding Dale N
Infectious diseases in clinical practice (Baltimore, Md.)
McDonald L Clifford
NEOMED College of Medicine
Treatment
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1001/jama.2016.4151" target="_blank" rel="noreferrer noopener">http://doi.org/10.1001/jama.2016.4151</a>
Pages
1864–1873
Issue
17
Volume
315
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011.
Publisher
An entity responsible for making the resource available
JAMA
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
2016-05
Subject
The topic of the resource
Adolescence; Adolescent; Adult; Aged; Ambulatory Care – Statistics and Numerical Data; Ambulatory Care/*statistics & numerical data; Anti-Bacterial Agents/*therapeutic use; Antibiotics – Therapeutic Use; Child; Female; Health Care Surveys; Human; Humans; Inappropriate Prescribing – Statistics and Numerical Data; Inappropriate Prescribing/*statistics & numerical data; Infant; Male; Middle Age; Middle Aged; Newborn; Otitis Media; Otitis Media – Drug Therapy; Pharyngitis – Drug Therapy; Pharyngitis/drug therapy; Physicians'/*statistics & numerical data; Practice Patterns; Preschool; Prevalence; Respiratory Tract Infections – Drug Therapy; Respiratory Tract Infections/drug therapy; Suppurative/*drug therapy; Surveys; United States
Creator
An entity primarily responsible for making the resource
Fleming-Dutra Katherine E; Hersh Adam L; Shapiro Daniel J; Bartoces Monina; Enns Eva A; File Thomas M Jr; Finkelstein Jonathan A; Gerber Jeffrey S; Hyun David Y; Linder Jeffrey A; Lynfield Ruth; Margolis David J; May Larissa S; Merenstein Daniel; Metlay Joshua P; Newland Jason G; Piccirillo Jay F; Roberts Rebecca M; Sanchez Guillermo V; Suda Katie J; Thomas Ann; Woo Teri Moser; Zetts Rachel M; Hicks Lauri A
Description
An account of the resource
IMPORTANCE: The National Action Plan for Combating Antibiotic-Resistant Bacteria set a goal of reducing inappropriate outpatient antibiotic use by 50% by 2020, but the extent of inappropriate outpatient antibiotic use is unknown. OBJECTIVE: To estimate the rates of outpatient oral antibiotic prescribing by age and diagnosis, and the estimated portions of antibiotic use that may be inappropriate in adults and children in the United States. DESIGN, SETTING, AND PARTICIPANTS: Using the 2010-2011 National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, annual numbers and population-adjusted rates with 95% confidence intervals of ambulatory visits with oral antibiotic prescriptions by age, region, and diagnosis in the United States were estimated. EXPOSURES: Ambulatory care visits. MAIN OUTCOMES AND MEASURES: Based on national guidelines and regional variation in prescribing, diagnosis-specific prevalence and rates of total and appropriate antibiotic prescriptions were determined. These rates were combined to calculate an estimate of the appropriate annual rate of antibiotic prescriptions per 1000 population. RESULTS: Of the 184,032 sampled visits, 12.6% of visits (95% CI, 12.0%-13.3%) resulted in antibiotic prescriptions. Sinusitis was the single diagnosis associated with the most antibiotic prescriptions per 1000 population (56 antibiotic prescriptions [95% CI, 48-64]), followed by suppurative otitis media (47 antibiotic prescriptions [95% CI, 41-54]), and pharyngitis (43 antibiotic prescriptions [95% CI, 38-49]). Collectively, acute respiratory conditions per 1000 population led to 221 antibiotic prescriptions (95% CI, 198-245) annually, but only 111 antibiotic prescriptions were estimated to be appropriate for these conditions. Per 1000 population, among all conditions and ages combined in 2010-2011, an estimated 506 antibiotic prescriptions (95% CI, 458-554) were written annually, and, of these, 353 antibiotic prescriptions were estimated to be appropriate antibiotic prescriptions. CONCLUSIONS AND RELEVANCE: In the United States in 2010-2011, there was an estimated annual antibiotic prescription rate per 1000 population of 506, but only an estimated 353 antibiotic prescriptions were likely appropriate, supporting the need for establishing a goal for outpatient antibiotic stewardship.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1001/jama.2016.4151" target="_blank" rel="noreferrer noopener">10.1001/jama.2016.4151</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2016
Adolescence
Adolescent
Adult
Aged
Ambulatory Care – Statistics and Numerical Data
Ambulatory Care/*statistics & numerical data
Anti-Bacterial Agents/*therapeutic use
Antibiotics – Therapeutic Use
Bartoces Monina
Child
Department of Internal Medicine
Enns Eva A
Female
File Thomas M Jr
Finkelstein Jonathan A
Fleming-Dutra Katherine E
Gerber Jeffrey S
Health Care Surveys
Hersh Adam L
Hicks Lauri A
Human
Humans
Hyun David Y
Inappropriate Prescribing – Statistics and Numerical Data
Inappropriate Prescribing/*statistics & numerical data
Infant
JAMA
Linder Jeffrey A
Lynfield Ruth
Male
Margolis David J
May Larissa S
Merenstein Daniel
Metlay Joshua P
Middle Age
Middle Aged
NEOMED College of Medicine
Newborn
Newland Jason G
Otitis Media
Otitis Media – Drug Therapy
Pharyngitis – Drug Therapy
Pharyngitis/drug therapy
Physicians'/*statistics & numerical data
Piccirillo Jay F
Practice Patterns
Preschool
Prevalence
Respiratory Tract Infections – Drug Therapy
Respiratory Tract Infections/drug therapy
Roberts Rebecca M
Sanchez Guillermo V
Shapiro Daniel J
Suda Katie J
Suppurative/*drug therapy
Surveys
Thomas Ann
United States
Woo Teri Moser
Zetts Rachel M
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/cis559" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/cis559</a>
Pages
S173–180
Volume
55 Suppl 3
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Summary of ceftaroline fosamil clinical trial studies and clinical safety.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2012
2012-09
Subject
The topic of the resource
Anti-Bacterial Agents/adverse effects/*therapeutic use; Bacterial/drug therapy; Cephalosporins/adverse effects/*therapeutic use; Clinical Trials as Topic; Humans; Pneumonia; Staphylococcal Skin Infections/drug therapy
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Wilcox Mark H; Stein Gary E
Description
An account of the resource
In October 2010, the new cephalosporin, ceftaroline fosamil, was approved by the US Food and Drug Administration for therapy of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The active metabolite, ceftaroline, demonstrates in vitro activity against typical bacterial pathogens most often associated with CABP or ABSSSIs, including resistant Gram-positive pathogens such as multidrug-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus. The efficacy and safety of ceftaroline fosamil was assessed in 2 large phase 3 programs of randomized, double-blind, clinical trials for CABP and ABSSSIs. For both indications, therapy with ceftaroline fosamil was observed to be noninferior to the comparator agents (ceftriaxone for CABP and vancomycin plus aztreonam for ABSSSIs) at both a standard test of cure assessment time (8-15 days after discontinuation of study drug) and an early assessment time point (day 3 or 4 of study). In the integrated analysis of the trials for CABP (FOCUS 1 and 2), clinical cure rates for the ceftaroline group were numerically higher than those for the ceftriaxone group (for the clinically evaluable population 84.3% vs 77.7%; difference: 6.6%; 95% confidence interval, 1.6%-11.8%). Among patients with CABP caused by S. pneumoniae, clinical cure rates were markedly higher in the ceftaroline treatment group than in the ceftriaxone treatment group (59 of 69 [85.5%] vs 48 of 70 [68.6%], respectively). For the ABSSSI studies (CANVAS 1 and 2), microbiologically evaluable (ME) success rates were similar between the treatment groups. Notably, the clinical cure rates in ME patients with methicillin-resistant S. aureus ABSSSIs were 142 of 152 (93.4%) and 115 of 122 (94.3%), for ceftaroline and vancomycin plus aztreonam, respectively, and did not differ from those achieved in infections due to methicillin-susceptible S. aureus (93.0%-94.5%). Ceftaroline fosamil was well tolerated, with a safety profile similar to the comparator agents used in these phase 3 trials.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/cis559" target="_blank" rel="noreferrer noopener">10.1093/cid/cis559</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2012
Anti-Bacterial Agents/adverse effects/*therapeutic use
Bacterial/drug therapy
Cephalosporins/adverse effects/*therapeutic use
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Clinical Trials as Topic
Department of Internal Medicine
File Thomas M Jr
Humans
NEOMED College of Medicine
Pneumonia
Staphylococcal Skin Infections/drug therapy
Stein Gary E
Wilcox Mark H
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.2165/00151829-200504020-00003" target="_blank" rel="noreferrer noopener">http://doi.org/10.2165/00151829-200504020-00003</a>
Pages
95–106
Issue
2
Volume
4
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Severe acute respiratory syndrome: pertinent clinical characteristics and therapy.
Publisher
An entity responsible for making the resource available
Treatments in respiratory medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
1905-06
Subject
The topic of the resource
Humans; Algorithms; Infection Control; *Severe Acute Respiratory Syndrome/*diagnosis/epidemiology/*therapy/transmission
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Tsang Kenneth W T
Description
An account of the resource
Severe acute respiratory syndrome (SARS) is a newly emerged infection that is caused by a previously unrecognized virus - a novel coronavirus designated as
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2165/00151829-200504020-00003" target="_blank" rel="noreferrer noopener">10.2165/00151829-200504020-00003</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Severe Acute Respiratory Syndrome/*diagnosis/epidemiology/*therapy/transmission
2005
Algorithms
Department of Internal Medicine
File Thomas M Jr
Humans
Infection Control
NEOMED College of Medicine
Treatments in respiratory medicine
Tsang Kenneth W T
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.2165/00003495-200363020-00005" target="_blank" rel="noreferrer noopener">http://doi.org/10.2165/00003495-200363020-00005</a>
Pages
181–205
Issue
2
Volume
63
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.
Publisher
An entity responsible for making the resource available
Drugs
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
1905-06
Subject
The topic of the resource
Adult; Humans; Microbial Sensitivity Tests; Anti-Infective Agents/*therapeutic use; Outpatients; Practice Guidelines as Topic; Clinical Trials as Topic; Community-Acquired Infections/drug therapy/microbiology; Treatment Failure; Inpatients; Macrolides/pharmacology/*therapeutic use; Drug Resistance; Pneumonia; Bacterial; Bacterial/*drug therapy/microbiology; Adjuvants; Immunologic/pharmacology/therapeutic use
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Tan James S
Description
An account of the resource
The significance of community-acquired pneumonia (CAP) has led to the publication of guidelines from numerous international organisations. Because the macrolide class of antimicrobials is active against most of the key pathogens associated with CAP, agents from this class are commonly included in recommendations from these guidelines. However, there are differences among the various guidelines concerning the positioning of the macrolides for empirical therapy. An important factor concerning the use of macrolides for CAP is the emergence of resistance of Streptococcus pneumoniae over the past decade. The rate of S. pneumoniae resistance to macrolides ranges from 4 to 70% of strains in worldwide surveillance studies. The most common mechanisms of resistance include methylation of a ribosomal target encoded by the erm gene and efflux of the macrolides by a cell membrane protein transporter, encoded by the mef gene. S. pneumoniae strains with the mef gene are resistant at a lower level (with minimum inhibitory concentration [MIC] values generally 1-16 microg/ml) than erm resistant strains; and it is possible that such strains may be inhibited if sufficiently high levels of macrolide can be obtained at the infected site. Currently mef-associated resistance predominates in North America, whereas erm predominates in Europe. Until recently, reports of failure of treatment of CAP with macrolides has been rare, particularly for patients with low-risk for drug-resistant strains. However, since 2000, several patients treated with an oral macrolide who have subsequently required admission to the hospital for macrolide-resistant S. pneumoniae (MRSP) bacteraemia have been reported in the literature. Major issues, which are fundamental to the use of the macrolides as recommended in the various guidelines, include the importance of providing therapy for 'atypical' pathogens and the clinical significance of MRSP. Presently, the macrolides are more prominently recommended in the North American guidelines than in other parts of the world. The difference in the emphasis placed on the importance of the atypical pathogens as well as the expression of MRSP in North America compared with Europe partly explains this variance.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2165/00003495-200363020-00005" target="_blank" rel="noreferrer noopener">10.2165/00003495-200363020-00005</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2003
Adjuvants
Adult
Anti-Infective Agents/*therapeutic use
Bacterial
Bacterial/*drug therapy/microbiology
Clinical Trials as Topic
Community-Acquired Infections/drug therapy/microbiology
Department of Internal Medicine
Drug Resistance
Drugs
File Thomas M Jr
Humans
Immunologic/pharmacology/therapeutic use
Inpatients
Macrolides/pharmacology/*therapeutic use
Microbial Sensitivity Tests
NEOMED College of Medicine
Outpatients
Pneumonia
Practice Guidelines as Topic
Tan James S
Treatment Failure
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/cir364" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/cir364</a>
Pages
S15–22
Volume
53 Suppl 1
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Strategies for improving antimicrobial use and the role of antimicrobial stewardship programs.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-08
Subject
The topic of the resource
*Drug Resistance; Anti-Bacterial Agents/administration & dosage/*therapeutic use; Bacterial; Bacterial Infections/*drug therapy/prevention & control; Bacterial/drug therapy; Bacteriuria/drug therapy; Centers for Medicare and Medicaid Services (U.S.); Community-Acquired Infections/drug therapy; Cross Infection/drug therapy; Drug Utilization; Hospitals; Humans; Pneumonia; Practice Guidelines as Topic; Public Health; Quality of Health Care/*standards; Surgical Wound Infection/drug therapy; United States
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Solomkin Joseph S; Cosgrove Sara E
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/cir364" target="_blank" rel="noreferrer noopener">10.1093/cid/cir364</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Drug Resistance
2011
Anti-Bacterial Agents/administration & dosage/*therapeutic use
Bacterial
Bacterial Infections/*drug therapy/prevention & control
Bacterial/drug therapy
Bacteriuria/drug therapy
Centers for Medicare and Medicaid Services (U.S.)
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Community-Acquired Infections/drug therapy
Cosgrove Sara E
Cross Infection/drug therapy
Department of Internal Medicine
Drug Utilization
File Thomas M Jr
Hospitals
Humans
NEOMED College of Medicine
Pneumonia
Practice Guidelines as Topic
Public Health
Quality of Health Care/*standards
Solomkin Joseph S
Surgical Wound Infection/drug therapy
United States
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1086/591398" target="_blank" rel="noreferrer noopener">http://doi.org/10.1086/591398</a>
Pages
S157–165
Volume
47 Suppl 3
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
What can we learn from the time course of untreated and partially treated community-onset Streptococcus pneumoniae pneumonia? A clinical perspective on superiority and noninferiority trial designs for mild community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2008
2008-12
Subject
The topic of the resource
*Research Design; Community-Acquired Infections/*drug therapy/microbiology; Disease Progression; Humans; Pneumococcal/*drug therapy/microbiology; Pneumonia; Randomized Controlled Trials as Topic/*methods; Streptococcus pneumoniae/*isolation & purification; Time Factors; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Schentag Jerome J
Description
An account of the resource
There are no well-designed placebo-controlled clinical trials in the recent era that precisely define the magnitude of the drug effect of antimicrobial therapy for mild community-acquired pneumonia (CAP). However, there is evidence that ineffective therapies, selected on the basis of the ratio of 24-h area under the concentration curve to minimum inhibitory concentration, associated with a discordant (nonsusceptible in vitro) specific agent (or no therapy) for mild CAP due to Streptococcus pneumoniae are associated with increased risk of progression to serious CAP. The relatively high rate of clinical success associated with appropriate antimicrobial treatment of mild CAP renders a standard outcome measure of clinical success an unlikely way to differentiate new agents. However, there may be an advantage in composite outcome assessments for mild CAP. Composite-outcomes end points that include time to resolution of morbidity, the use of patient reported-outcomes instruments, and biomarkers are recommended for future studies. Because the composite rate of success in recent randomized clinical trials exceeds 90%, it would seem that a noninferiority margin of 10% is reasonable for trials for mild CAP.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1086/591398" target="_blank" rel="noreferrer noopener">10.1086/591398</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Research Design
2008
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Community-Acquired Infections/*drug therapy/microbiology
Department of Internal Medicine
Disease Progression
File Thomas M Jr
Humans
NEOMED College of Medicine
Pneumococcal/*drug therapy/microbiology
Pneumonia
Randomized Controlled Trials as Topic/*methods
Schentag Jerome J
Streptococcus pneumoniae/*isolation & purification
Time Factors
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/ciw490" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/ciw490</a>
Pages
1007–1016
Issue
8
Volume
63
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
2016-10
Subject
The topic of the resource
*clinical trial; *community-acquired; *pneumonia; *solithromycin; *Streptococcus pneumoniae; 80 and over; Administration; Adult; Aged; Anti-Bacterial Agents/*administration & dosage/adverse effects; Bacterial; Bacterial/diagnosis/*drug therapy/*microbiology; Community-Acquired Infections/diagnosis/*drug therapy/*microbiology; Comorbidity; Drug Resistance; Female; Fluoroquinolones/*administration & dosage/adverse effects; Humans; Intravenous; Macrolides/*administration & dosage/adverse effects; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Oral; Pneumonia; Treatment Outcome; Triazoles/*administration & dosage/adverse effects
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Rewerska Barbara; Vucinic-Mihailovic Violeta; Gonong Joven Roque V; Das Anita F; Keedy Kara; Taylor David; Sheets Amanda; Fernandes Prabhavathi; Oldach David; Jamieson Brian D
Description
An account of the resource
BACKGROUND: Solithromycin, a novel macrolide antibiotic with both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia. METHODS: A total of 863 adults with community-acquired bacterial pneumonia (Pneumonia Outcomes Research Team [PORT] class II-IV) were randomized 1:1 to receive either intravenous-to-oral solithromycin or moxifloxacin for 7 once-daily doses. All patients received 400 mg intravenously on day 1 and were permitted to switch to oral dosing when clinically indicated. The primary objective was to demonstrate noninferiority (10% margin) of solithromycin to moxifloxacin in achievement of early clinical response (ECR) assessed 3 days after first dose in the intent-to-treat (ITT) population. Secondary endpoints included demonstrating noninferiority in ECR in the microbiological ITT population (micro-ITT) and determination of investigator-assessed success rates at the short-term follow-up (SFU) visit 5-10 days posttherapy. RESULTS: In the ITT population, 79.3% of solithromycin patients and 79.7% of moxifloxacin patients achieved ECR (treatment difference, -0.46; 95% confidence interval [CI], -6.1 to 5.2). In the micro-ITT population, 80.3% of solithromycin patients and 79.1% of moxifloxacin patients achieved ECR (treatment difference, 1.26; 95% CI, -8.1 to 10.6). In the ITT population, 84.6% of solithromycin patients and 88.6% of moxifloxacin patients achieved clinical success at SFU based on investigator assessment. Mostly mild/moderate infusion events led to higher incidence of adverse events overall in the solithromycin group. Other adverse events were comparable between treatment groups. CONCLUSIONS: Intravenous-to-oral solithromycin was noninferior to intravenous-to-oral moxifloxacin. Solithromycin has potential to provide an intravenous and oral option for monotherapy for community-acquired bacterial pneumonia. CLINICAL TRIALS REGISTRATION: NCT01968733.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/ciw490" target="_blank" rel="noreferrer noopener">10.1093/cid/ciw490</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*clinical trial
*Community-acquired
*Pneumonia
*solithromycin
*Streptococcus pneumoniae
2016
80 and over
Administration
Adult
Aged
Anti-Bacterial Agents/*administration & dosage/adverse effects
Bacterial
Bacterial/diagnosis/*drug therapy/*microbiology
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Community-Acquired Infections/diagnosis/*drug therapy/*microbiology
Comorbidity
Das Anita F
Department of Internal Medicine
Drug Resistance
Female
Fernandes Prabhavathi
File Thomas M Jr
Fluoroquinolones/*administration & dosage/adverse effects
Gonong Joven Roque V
Humans
Intravenous
Jamieson Brian D
Keedy Kara
Macrolides/*administration & dosage/adverse effects
Male
Microbial Sensitivity Tests
Middle Aged
Moxifloxacin
NEOMED College of Medicine
Oldach David
Oral
Pneumonia
Rewerska Barbara
Sheets Amanda
Taylor David
Treatment Outcome
Triazoles/*administration & dosage/adverse effects
Vucinic-Mihailovic Violeta
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ijantimicag.2008.07.019" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ijantimicag.2008.07.019</a>
Pages
58–64
Issue
1
Volume
33
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic.
Publisher
An entity responsible for making the resource available
International journal of antimicrobial agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2009
2009-01
Subject
The topic of the resource
*Anti-Bacterial Agents/pharmacokinetics/therapeutic use; *Community-Acquired Infections/drug therapy/microbiology/physiopathology/prevention & control; *Models; *Pneumonia; Aged; Area Under Curve; Bacterial/drug therapy/microbiology/physiopathology/prevention & control; Biological; Bronchitis; Chronic Obstructive/drug therapy/microbiology/*physiopathology; Chronic/drug therapy/microbiology/physiopathology; Disease Progression; Female; Humans; Lung Diseases/complications/drug therapy/microbiology; Lung/microbiology; Male; Microbial Sensitivity Tests; Middle Aged; Pneumococcal/drug therapy/microbiology/physiopathology/prevention & control; Pneumonia; Pulmonary Disease; Severity of Illness Index; Streptococcus pneumoniae/*drug effects
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Monte Scott V; Schentag Jerome J; Paladino Joseph A; Klugman Keith P; Lavin Bruce; Yu Victor L; Singer Mendel E; Adelman Martin H
Description
An account of the resource
Patients with chronic obstructive pulmonary disease (COPD) may progress to community-acquired pneumonia (CAP), but there has been no formal study of the factors responsible. We studied the influence of severity of underlying lung disease, pathogen characteristics and the ratio of the area under the concentration-time curve from 0-24h to minimum inhibitory concentration (AUC24/MIC), i.e. the area under the inhibitory curve (AUIC), during the progression from acute exacerbation of chronic bronchitis (AECB) in COPD to CAP. The model parameters were derived from a multinational database of 3885 patients with AECB or CAP (April 1996 to July 2006). Patients with underlying COPD were evaluated in two separate analyses: infection progression between COPD and CAP within Global Initiative for Chronic Obstructive Lung Disease (GOLD)-like grouping (GLG); and distribution of pathogen by GLG, CAP and AECB. Secondary analyses examined the impact of target AUIC attainment on progression to CAP for Streptococcus pneumoniae. The relative impact of GLG and AUIC were modelled in multivariate logistic regression for S. pneumoniae. Progression to CAP linked directly with GLG I/II, III and IV (18.3%, 31.7% and 48.9%, respectively; P \textless 0.001). Progression to CAP was strongly associated with S. pneumoniae (57.3%), whilst other pathogens were predominant in AECB that did not progress to CAP (61.7%) (P = 0.002). AUIC \textgreater or = 100 was associated with AECB (65.1%) and AUIC \textless 100 with CAP (91.7%) (P \textless 0.001). In conclusion, the frequency of progression to CAP increases directly with GLG. For S. pneumoniae, achieving an AUIC \textgreater or =100 can attenuate progression, regardless of GLG. Thus, AUIC \textgreater or = 100 appears to be a viable antibiotic selection strategy to protect patients with S. pneumoniae from developing CAP.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ijantimicag.2008.07.019" target="_blank" rel="noreferrer noopener">10.1016/j.ijantimicag.2008.07.019</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Anti-Bacterial Agents/pharmacokinetics/therapeutic use
*Community-Acquired Infections/drug therapy/microbiology/physiopathology/prevention & control
*Models
*Pneumonia
2009
Adelman Martin H
Aged
Area Under Curve
Bacterial/drug therapy/microbiology/physiopathology/prevention & control
Biological
Bronchitis
Chronic Obstructive/drug therapy/microbiology/*physiopathology
Chronic/drug therapy/microbiology/physiopathology
Department of Internal Medicine
Disease Progression
Female
File Thomas M Jr
Humans
International journal of antimicrobial agents
Klugman Keith P
Lavin Bruce
Lung Diseases/complications/drug therapy/microbiology
Lung/microbiology
Male
Microbial Sensitivity Tests
Middle Aged
Monte Scott V
NEOMED College of Medicine
Paladino Joseph A
Pneumococcal/drug therapy/microbiology/physiopathology/prevention & control
Pneumonia
Pulmonary Disease
Schentag Jerome J
Severity of Illness Index
Singer Mendel E
Streptococcus pneumoniae/*drug effects
Yu Victor L
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1185/030079904X2556" target="_blank" rel="noreferrer noopener">http://doi.org/10.1185/030079904X2556</a>
Pages
1473–1481
Issue
9
Volume
20
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Current medical research and opinion
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-09
Subject
The topic of the resource
*Levofloxacin; Administration; Adult; Anti-Bacterial Agents/*administration & dosage/economics; Bacterial/*drug therapy; Community-Acquired Infections/drug therapy; Drug Administration Schedule; Drug Costs; Female; Humans; Infusions; Intravenous; Male; Ofloxacin/*administration & dosage/economics; Oral; Pneumonia; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Milkovich Gary; Tennenberg Alan M; Xiang Jim X; Khashab Mohammed M; Zadeikis Neringa
Description
An account of the resource
OBJECTIVE: To evaluate the time to symptom resolution and i.v.-to-p.o. transition in community-acquired pneumonia (CAP) patients treated with 750 mg or 500 mg levofloxacin. RESEARCH DESIGN: A retrospective, subset analysis of a multicenter, randomized, double-blind, controlled trial comparing 750 mg levofloxacin for 5 days to 500 mg levofloxacin for 10 days for the treatment of CAP. PATIENTS AND METHODS: A total of 528 CAP patients were included. Baseline symptoms were re-evaluated on Day 3 of therapy, and time to i.v.-to-p.o. transition was recorded for inpatients. RESULTS: For the overall population, 67.4% of patients receiving 750 mg levofloxacin had resolution of fever by Day 3 of therapy, compared to 54.6% of 500 mg treated patients (P = 0.006). Patients who started on 750 mg levofloxacin i.v. (N = 108) transitioned to p.o. in an average of 2.68 days while those starting on 500 mg i.v. (N = 124) transitioned in 2.95 days (P = 0.144). The median time for i.v.-to-p.o. switch was 2.35 days and 2.75 days for patients receiving 750 mg and 500 mg levofloxacin, respectively (P = 0.098, log rank test). By Day 3 of therapy, 68% of patients receiving the 750 mg dose had transitioned from i.v. to p.o. levofloxacin, compared with 61% of the 500 mg group (P = 0.280). The safety profiles were comparable for the two regimens. CONCLUSIONS: The 750 mg levofloxacin dose resulted in a greater proportion of patients with resolution of CAP symptoms by Day 3 when compared with 500 mg therapy. Consequently, the 750 mg regimen trended toward more rapid transition to p.o., potentially resulting in lower overall drug costs. Time to switch from i.v. to p.o. was determined by the investigators' discretion rather than a set protocol. Additionally, length of stay data was not collected in this study, which can significantly impact overall healthcare costs. Further research is required to fully understand the economic impact of the 750 mg, 5-day levofloxacin regimen.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1185/030079904X2556" target="_blank" rel="noreferrer noopener">10.1185/030079904X2556</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Levofloxacin
2004
Administration
Adult
Anti-Bacterial Agents/*administration & dosage/economics
Bacterial/*drug therapy
Community-Acquired Infections/drug therapy
Current medical research and opinion
Department of Internal Medicine
Drug Administration Schedule
Drug Costs
Female
File Thomas M Jr
Humans
Infusions
Intravenous
Khashab Mohammed M
Male
Milkovich Gary
NEOMED College of Medicine
Ofloxacin/*administration & dosage/economics
Oral
Pneumonia
Tennenberg Alan M
Treatment Outcome
Xiang Jim X
Zadeikis Neringa
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3810/pgm.2010.03.2130" target="_blank" rel="noreferrer noopener">http://doi.org/10.3810/pgm.2010.03.2130</a>
Pages
130–141
Issue
2
Volume
122
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Burden of community-acquired pneumonia in North American adults.
Publisher
An entity responsible for making the resource available
Postgraduate medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-03
Subject
The topic of the resource
Adult; Humans; Incidence; Risk Factors; Cost of Illness; Length of Stay/statistics & numerical data; North America/epidemiology; Health Care Costs; Health Status Indicators; North America; Human; Community-Acquired Infections/economics/epidemiology/microbiology/prevention & control; Hospitalization/economics/statistics & numerical data; Pneumococcal Vaccines; Streptococcus pneumoniae; Pneumonia; Bacterial/economics/*epidemiology/microbiology/prevention & control; Pneumococcal/economics/epidemiology/mortality/prevention & control; Economic Aspects of Illness; Streptococcus; Pneumococcal Vaccine; Length of Stay – Statistics and Numerical Data; Bacterial – Epidemiology; Community-Acquired Infections – Epidemiology; Community-Acquired Infections – Microbiology; Bacterial – Economics; Bacterial – Microbiology; Bacterial – Mortality; Bacterial – Prevention and Control; Community-Acquired Infections – Economics; Community-Acquired Infections – Prevention and Control; Hospitalization – Economics; Hospitalization – Statistics and Numerical Data
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Marrie Thomas J
Description
An account of the resource
To determine the burden of community-acquired pneumonia (CAP) affecting adults in North America, a comprehensive literature review was conducted to examine the incidence, morbidity and mortality, etiology, antibiotic resistance, and economic impact of CAP in this population. In the United States, there were approximately 4.2 million ambulatory care visits for pneumonia in 2006. Pneumonia and influenza continue to be a common cause of death in the United States (ranked eighth) and Canada (ranked seventh). In 2005, there were \textgreater60,000 deaths due to pneumonia in persons aged\textgreateror=15 years in the United States alone. The hospitalization rate for all infectious diseases increased from 1525 hospitalizations per 100 000 persons in 1998 to 1667 per 100 000 persons in 2005. Admission to an intensive care unit was required in 10% to 20% of patients hospitalized with pneumonia. The mean length of stay for pneumonia was \textgreateror=5 days and the 30-day rehospitalization rate was as high as 20%. Mortality was highest for CAP patients who were hospitalized; the 30-day mortality rate was as high as 23%. All-cause mortality for CAP patients was as high as 28% within 1 year. Streptococcus pneumoniae continues to be the most frequently identified pathogen associated with CAP, and pneumococcal resistance to antimicrobials may make treatment more difficult. The economic burden associated with CAP remains substantial at \textgreater$17 billion annually in the United States. Despite the availability and widespread adherence to recommended treatment guidelines, CAP continues to present a significant burden in adults. Furthermore, given the aging population in North America, clinicians can expect to encounter an increasing number of adult patients with CAP. Given the significance of the disease burden, the potential benefit of pneumococcal vaccination in adults is substantial.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3810/pgm.2010.03.2130" target="_blank" rel="noreferrer noopener">10.3810/pgm.2010.03.2130</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
Adult
Bacterial – Economics
Bacterial – Epidemiology
Bacterial – Microbiology
Bacterial – Mortality
Bacterial – Prevention and Control
Bacterial/economics/*epidemiology/microbiology/prevention & control
Community-Acquired Infections – Economics
Community-Acquired Infections – Epidemiology
Community-Acquired Infections – Microbiology
Community-Acquired Infections – Prevention and Control
Community-Acquired Infections/economics/epidemiology/microbiology/prevention & control
Cost of Illness
Department of Internal Medicine
Economic Aspects of Illness
File Thomas M Jr
Health Care Costs
Health Status Indicators
Hospitalization – Economics
Hospitalization – Statistics and Numerical Data
Hospitalization/economics/statistics & numerical data
Human
Humans
Incidence
Length of Stay – Statistics and Numerical Data
Length of Stay/statistics & numerical data
Marrie Thomas J
NEOMED College of Medicine
North America
North America/epidemiology
Pneumococcal Vaccine
Pneumococcal Vaccines
Pneumococcal/economics/epidemiology/mortality/prevention & control
Pneumonia
Postgraduate medicine
Risk Factors
Streptococcus
Streptococcus pneumoniae
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.idc.2012.11.005" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.idc.2012.11.005</a>
Pages
99–114
Issue
1
Volume
27
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?
Publisher
An entity responsible for making the resource available
Infectious disease clinics of North America
Date
A point or period of time associated with an event in the lifecycle of the resource
2013
2013-03
Subject
The topic of the resource
Anti-Bacterial Agents/*therapeutic use; Antibiotic Prophylaxis; Antibiotics – Therapeutic Use; Clinical Trials; Clinical Trials as Topic; Community-Acquired Infections – Drug Therapy; Community-Acquired Infections – Microbiology; Community-Acquired Infections/drug therapy/microbiology; Humans; Pneumonia – Drug Therapy; Pneumonia – Microbiology; Pneumonia/*drug therapy/microbiology
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Marrie Thomas J
Description
An account of the resource
The present controversy regarding the need to cover atypical pathogens in the empiric therapy of community-acquired pneumonia is related to several issues, including the relevance of terminology, imprecise diagnostic methods, and perceived contradictory results of published evidence. Studies evaluating the time to clinical recovery and the use of earlier endpoints for evaluation suggest that appropriate therapy provides a benefit if an atypical pathogen is a pathogen. Because recent surveillance studies suggest these pathogens are common and until there is the availability of accurate, cost-effective, and easily interpreted laboratory tests to provide the etiologic diagnosis at the time of point of care, empiric therapy of atypical pathogens is supported.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.idc.2012.11.005" target="_blank" rel="noreferrer noopener">10.1016/j.idc.2012.11.005</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2013
Anti-Bacterial Agents/*therapeutic use
Antibiotic Prophylaxis
Antibiotics – Therapeutic Use
Clinical Trials
Clinical Trials as Topic
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections – Microbiology
Community-Acquired Infections/drug therapy/microbiology
Department of Internal Medicine
File Thomas M Jr
Humans
Infectious disease clinics of North America
Marrie Thomas J
NEOMED College of Medicine
Pneumonia – Drug Therapy
Pneumonia – Microbiology
Pneumonia/*drug therapy/microbiology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/jac/dkm119" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/jac/dkm119</a>
Pages
112–120
Issue
1
Volume
60
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
Publisher
An entity responsible for making the resource available
The Journal of antimicrobial chemotherapy
Date
A point or period of time associated with an event in the lifecycle of the resource
2007
2007-07
Subject
The topic of the resource
80 and over; Adolescent; Adult; Aged; Anti-Bacterial Agents/*administration & dosage/adverse effects/therapeutic use; Bacterial/*drug therapy/microbiology; Community-Acquired Infections/*drug therapy/microbiology; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones/*administration & dosage/adverse effects/therapeutic use; Gemifloxacin; Humans; Male; Middle Aged; Naphthyridines/*administration & dosage/adverse effects/therapeutic use; Pneumococcal/drug therapy/microbiology; Pneumonia; Streptococcus pneumoniae/isolation & purification; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Mandell Lionel A; Tillotson Glenn; Kostov Kosta; Georgiev Ognian
Description
An account of the resource
OBJECTIVES: Short-course therapy has been advocated for the treatment of community-acquired pneumonia (CAP). We compared the efficacy and safety of 5 and 7 day courses of gemifloxacin for outpatient treatment of mild-moderate CAP. PATIENTS AND METHODS: In a multicentre, double-blind, parallel group study, patients were randomized to receive 320 mg of oral gemifloxacin once daily for 5 or 7 days. Over 95% of all patients in each cohort had a Fine score of
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/jac/dkm119" target="_blank" rel="noreferrer noopener">10.1093/jac/dkm119</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2007
80 and over
Adolescent
Adult
Aged
Anti-Bacterial Agents/*administration & dosage/adverse effects/therapeutic use
Bacterial/*drug therapy/microbiology
Community-Acquired Infections/*drug therapy/microbiology
Department of Internal Medicine
Double-Blind Method
Drug Administration Schedule
Female
File Thomas M Jr
Fluoroquinolones/*administration & dosage/adverse effects/therapeutic use
Gemifloxacin
Georgiev Ognian
Humans
Kostov Kosta
Male
Mandell Lionel A
Middle Aged
Naphthyridines/*administration & dosage/adverse effects/therapeutic use
NEOMED College of Medicine
Pneumococcal/drug therapy/microbiology
Pneumonia
Streptococcus pneumoniae/isolation & purification
The Journal of antimicrobial chemotherapy
Tillotson Glenn
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1086/657313" target="_blank" rel="noreferrer noopener">http://doi.org/10.1086/657313</a>
Pages
1395–1405
Issue
12
Volume
51
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-12
Subject
The topic of the resource
80 and over; Administration; Adult; Aged; Anti-Bacterial Agents/*administration & dosage/*adverse effects; Bacterial/*drug therapy; Ceftriaxone/*administration & dosage/*adverse effects; Cephalosporins/*administration & dosage/*adverse effects; Community-Acquired Infections/drug therapy; Double-Blind Method; Female; Humans; Infusions; Intravenous; Male; Middle Aged; Oral; Pneumonia; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Low Donald E; Eckburg Paul B; Talbot George H; Friedland H David; Lee Jon; Llorens Lily; Critchley Ian; Thye Dirk
Description
An account of the resource
BACKGROUND: Ceftaroline, the active form of ceftaroline fosamil, is a broad-spectrum cephalosporin with bactericidal activity against pathogens causing community-acquired pneumonia (CAP), including Streptococcus pneumoniae. Ceftaroline was evaluated for the treatment of CAP in 2 randomized, double-blind, multicenter trials: Ceftaroline Community Acquired Pneumonia Trial versus Ceftriaxone in Hospitalized Patients (FOCUS) 1 and FOCUS 2. METHODS: Patients hospitalized (but not admitted to an intensive care unit) with Pneumonia Outcomes Research Team risk class III or IV CAP requiring intravenous therapy were randomized to ceftaroline 600 mg every 12 h or ceftriaxone 1 g every 24 h for 5-7 days. Patients in FOCUS 1 received 2 doses of oral clarithromycin 500 mg every 12 h on day 1. RESULTS: In the individual trials, clinical cure rates in the clinically evaluable (CE) population for ceftaroline versus ceftriaxone were as follows: FOCUS 1, 86.6% vs 78.2% (difference, 8.4%; 95% confidence interval [CI], 1.4%-15.4%); FOCUS 2, 82.1% vs 77.2% (difference, 4.9%; 95% CI, -2.5% to 12.5%). In the integrated analysis, 614 patients received ceftaroline and 614 received ceftriaxone. Of the CE patients treated with ceftaroline, 84.3% achieved clinical cure, compared with 77.7% of ceftriaxone-treated patients (difference, 6.7%; 95% CI, 1.6%-11.8%). Clinical cure rates in the modified intent-to-treat efficacy population were 82.6% versus 76.6% for ceftaroline and ceftriaxone (difference, 6.0%; 95% CI, 1.4%-10.7%). Ceftaroline and ceftriaxone were well tolerated; rates of adverse events, serious adverse events, deaths, and premature discontinuations caused by an adverse event were similar in both treatment arms. CONCLUSIONS: Ceftaroline was noninferior to ceftriaxone in the individual trials. In this integrated analysis, clinical cure rates for the ceftaroline group were numerically higher than those for the ceftriaxone group. Ceftaroline was well tolerated, with a safety profile similar to that of ceftriaxone.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1086/657313" target="_blank" rel="noreferrer noopener">10.1086/657313</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
80 and over
Administration
Adult
Aged
Anti-Bacterial Agents/*administration & dosage/*adverse effects
Bacterial/*drug therapy
Ceftriaxone/*administration & dosage/*adverse effects
Cephalosporins/*administration & dosage/*adverse effects
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Community-Acquired Infections/drug therapy
Critchley Ian
Department of Internal Medicine
Double-Blind Method
Eckburg Paul B
Female
File Thomas M Jr
Friedland H David
Humans
Infusions
Intravenous
Lee Jon
Llorens Lily
Low Donald E
Male
Middle Aged
NEOMED College of Medicine
Oral
Pneumonia
Talbot George H
Thye Dirk
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/jac/dkr096" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/jac/dkr096</a>
Pages
iii19–32
Volume
66 Suppl 3
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
The Journal of antimicrobial chemotherapy
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-04
Subject
The topic of the resource
80 and over; 80 and Over; Aged; Bacteria; Bacteria/isolation & purification; Bacterial – Drug Therapy; Bacterial/*drug therapy; Ceftriaxone – Administration and Dosage; Ceftriaxone – Adverse Effects; Ceftriaxone/administration & dosage/adverse effects; Cephalosporins – Administration and Dosage; Cephalosporins – Adverse Effects; Cephalosporins/*administration & dosage/*adverse effects; Community-Acquired Infections – Drug Therapy; Community-Acquired Infections/*drug therapy; Double-Blind Method; Double-Blind Studies; Female; Human; Humans; Infusions; Intravenous; Male; Middle Age; Middle Aged; Pneumonia; Randomized Controlled Trials; Treatment Outcome; Treatment Outcomes
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Low Donald E; Eckburg Paul B; Talbot George H; Friedland H David; Lee Jon; Llorens Lily; Critchley Ian A; Thye Dirk A
Description
An account of the resource
OBJECTIVES: Ceftaroline, the active form of the prodrug ceftaroline fosamil, is a novel cephalosporin with bactericidal activity against important pathogens associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and common Gram-negative pathogens. FOCUS 1 is a randomized, double-blinded, Phase III study that was conducted to evaluate the efficacy and safety of ceftaroline fosamil in treating patients with CAP. The primary objective was to determine non-inferiority [lower limit of 95% confidence interval (CI) \textgreater/= -10%] in clinical cure rates achieved with ceftaroline fosamil compared with those achieved with ceftriaxone in the clinically evaluable (CE) and modified intent-to-treat efficacy (MITTE) populations. METHODS: Patients hospitalized in a non-intensive care unit setting with CAP of Pneumonia Outcomes Research Team (PORT) risk class III or IV requiring intravenous (iv) therapy were randomized (1:1) to receive 600 mg of ceftaroline fosamil iv every 12 h or 1 g of ceftriaxone iv every 24 h. Patients also received two 500 mg doses of oral clarithromycin every 12 h administered on day 1. Clinical cure, microbiological response, adverse events (AEs) and laboratory tests were assessed. FOCUS 1 registration number NCT00621504 (http://clinicaltrials.gov/ct2/show/NCT00621504). RESULTS: Of 613 enrolled patients, 298 received ceftaroline fosamil and 308 received ceftriaxone. Baseline characteristics between treatment groups were comparable. Clinical cure rates were as follows: CE population, 86.6% (194/224) for ceftaroline fosamil and 78.2% (183/234) for ceftriaxone [difference (95% CI), 8.4% (1.4, 15.4)]; and MITTE population, 83.8% (244/291) for ceftaroline fosamil and 77.7% (233/300) for ceftriaxone [difference (95% CI), 6.2% (-0.2, 12.6)]. Clinical cure rates for CAP caused by S. pneumoniae in the microbiological MITTE population were 88.9% (24/27) and 66.7% (20/30) for ceftaroline fosamil and ceftriaxone, respectively. Both agents were well tolerated, with similar rates of AEs, serious AEs, deaths and discontinuations because of an AE. The most common AEs for ceftaroline fosamil-treated patients were diarrhoea, headache, insomnia and nausea, and the most common AEs for ceftriaxone-treated patients were hypokalaemia, hypertension, nausea and diarrhoea. CONCLUSIONS: Ceftaroline fosamil demonstrated high clinical cure and microbiological response rates in hospitalized patients with CAP of PORT risk class III or IV. Ceftaroline fosamil was well tolerated, with a safety profile similar to that of ceftriaxone and consistent with the cephalosporin class. In this study, ceftaroline fosamil was an effective and well-tolerated treatment option for CAP.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/jac/dkr096" target="_blank" rel="noreferrer noopener">10.1093/jac/dkr096</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2011
80 and over
Aged
Bacteria
Bacteria/isolation & purification
Bacterial – Drug Therapy
Bacterial/*drug therapy
Ceftriaxone – Administration and Dosage
Ceftriaxone – Adverse Effects
Ceftriaxone/administration & dosage/adverse effects
Cephalosporins – Administration and Dosage
Cephalosporins – Adverse Effects
Cephalosporins/*administration & dosage/*adverse effects
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections/*drug therapy
Critchley Ian A
Department of Internal Medicine
Double-Blind Method
Double-Blind Studies
Eckburg Paul B
Female
File Thomas M Jr
Friedland H David
Human
Humans
Infusions
Intravenous
Lee Jon
Llorens Lily
Low Donald E
Male
Middle Age
Middle Aged
NEOMED College of Medicine
Pneumonia
RANDOMIZED controlled trials
Talbot George H
The Journal of antimicrobial chemotherapy
Thye Dirk A
Treatment Outcome
Treatment Outcomes
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0924-8579(02)00130-9" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0924-8579(02)00130-9</a>
Pages
235–247
Issue
4
Volume
20
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
Publisher
An entity responsible for making the resource available
International journal of antimicrobial agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2002
2002-10
Subject
The topic of the resource
*Treatment Outcome; 80 and over; Adolescent; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination/administration & dosage/*pharmacokinetics/pharmacology/*therapeutic use; Amoxicillin/adverse effects/therapeutic use; Bacterial; Bacterial/drug therapy/immunology; Bronchitis/drug therapy/microbiology; Combination/adverse effects/*therapeutic use; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Drug Therapy; Female; Follow-Up Studies; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multicenter Studies as Topic; Pneumonia; Respiratory Tract Infections/*drug therapy/metabolism/microbiology; Streptococcal Infections/*drug therapy/metabolism/microbiology; Streptococcus pneumoniae/*drug effects
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Jacobs Michael R; Poole Michael D; Wynne Brian
Description
An account of the resource
The efficacy of a new pharmacokinetically enhanced formulation of amoxycillin/clavulanate (AMX/CA) 2000/125 mg, twice daily, designed to provide adequate levels of amoxycillin over the 12-h dosing interval to eradicate penicillin-resistant Streptococcus pneumoniae (PRSP) with amoxycillin (+/-clavulanic acid) MICs of
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0924-8579(02)00130-9" target="_blank" rel="noreferrer noopener">10.1016/s0924-8579(02)00130-9</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Treatment Outcome
2002
80 and over
Adolescent
Adult
Aged
Amoxicillin-Potassium Clavulanate Combination/administration & dosage/*pharmacokinetics/pharmacology/*therapeutic use
Amoxicillin/adverse effects/therapeutic use
Bacterial
Bacterial/drug therapy/immunology
Bronchitis/drug therapy/microbiology
Combination/adverse effects/*therapeutic use
Department of Internal Medicine
Double-Blind Method
Drug Administration Schedule
Drug Resistance
Drug Therapy
Female
File Thomas M Jr
Follow-Up Studies
Humans
International journal of antimicrobial agents
Jacobs Michael R
Male
Microbial Sensitivity Tests
Middle Aged
Multicenter Studies as Topic
NEOMED College of Medicine
Pneumonia
Poole Michael D
Respiratory Tract Infections/*drug therapy/metabolism/microbiology
Streptococcal Infections/*drug therapy/metabolism/microbiology
Streptococcus pneumoniae/*drug effects
Wynne Brian
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1378/chest.125.5.1888" target="_blank" rel="noreferrer noopener">http://doi.org/10.1378/chest.125.5.1888</a>
Pages
1888–1901
Issue
5
Volume
125
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Chest
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-05
Subject
The topic of the resource
Humans; United States; Practice Guidelines as Topic; Canada; Europe; Community-Acquired Infections/drug therapy; Fluoroquinolones/therapeutic use; Lactams/therapeutic use; Macrolides/therapeutic use; Drug Resistance; Pneumonia; Bacterial; Bacterial/*drug therapy
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Garau Javier; Blasi Francesco; Chidiac Christian; Klugman Keith; Lode Hartmut; Lonks John R; Mandell Lionel; Ramirez Julio; Yu Victor
Description
An account of the resource
Empiric antimicrobial prescribing for community-acquired pneumonia remains a challenge, despite the availability of treatment guidelines. A number of key differences exist between North American and European guidelines, mainly in the outpatient setting. The North American approach is to use initial antimicrobial therapy, which provides coverage for Streptococcus pneumoniae plus atypical pathogens. Europeans tend to focus on providing pneumococcal coverage with less emphasis on covering for an atypical pathogen. Ambulatory patients without comorbidity are more likely to receive macrolide therapy in North America, whereas in Europe these patients would probably receive a beta-lactam agent. Major issues that are fundamental to this difference include the importance of providing therapy for atypical pathogens and the clinical significance of macrolide-resistant S pneumoniae. Prospective data are required to evaluate which of these two approaches offers clinical superiority.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1378/chest.125.5.1888" target="_blank" rel="noreferrer noopener">10.1378/chest.125.5.1888</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2004
Bacterial
Bacterial/*drug therapy
Blasi Francesco
Canada
Chest
Chidiac Christian
Community-Acquired Infections/drug therapy
Department of Internal Medicine
Drug Resistance
Europe
File Thomas M Jr
Fluoroquinolones/therapeutic use
Garau Javier
Humans
Klugman Keith
Lactams/therapeutic use
Lode Hartmut
Lonks John R
Macrolides/therapeutic use
Mandell Lionel
NEOMED College of Medicine
Pneumonia
Practice Guidelines as Topic
Ramirez Julio
United States
Yu Victor
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1038/ncprheum0684" target="_blank" rel="noreferrer noopener">http://doi.org/10.1038/ncprheum0684</a>
Pages
16–17
Issue
1
Volume
4
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Is the risk of serious infections increased in patients with RA who receive treatment with antirheumatic drugs?
Publisher
An entity responsible for making the resource available
Nature clinical practice. Rheumatology
Date
A point or period of time associated with an event in the lifecycle of the resource
2008
2008-01
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; File Elizabeth A
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1038/ncprheum0684" target="_blank" rel="noreferrer noopener">10.1038/ncprheum0684</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2008
Department of Internal Medicine
File Elizabeth A
File Thomas M Jr
Nature clinical practice. Rheumatology
NEOMED College of Medicine
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ijantimicag.2017.01.043" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ijantimicag.2017.01.043</a>
Pages
247–251
Issue
2
Volume
50
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
Publisher
An entity responsible for making the resource available
International journal of antimicrobial agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
2017-08
Subject
The topic of the resource
80 and over; Adult; Aged; Anti-Bacterial Agents/adverse effects/*therapeutic use; Atypical pathogen; Bacterial/*drug therapy; Ceftaroline fosamil; Ceftriaxone/adverse effects/*therapeutic use; Cephalosporins/adverse effects/*therapeutic use; Chlamydial Pneumonia; Chlamydophila pneumoniae; Clinical Trials; Combination/adverse effects/methods; Community-Acquired Infections/*drug therapy; Community-acquired pneumonia; Double-Blind Method; Drug Therapy; Female; Humans; Legionella pneumophila; Macrolide; Macrolides/adverse effects/*therapeutic use; Male; Middle Aged; Mycoplasma; Mycoplasma pneumoniae; Phase III as Topic; Pneumonia; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Eckburg Paul B; Talbot George H; Llorens Lily; Friedland H David
Description
An account of the resource
BACKGROUND: Therapy directed against atypical pathogens in patients with community-acquired pneumonia (CAP) is often recommended. This post-hoc analysis evaluated the effect of addition of a macrolide to ceftaroline fosamil or ceftriaxone treatment in atypical CAP. METHODS: Two phase 3, double-blind, comparative safety and efficacy studies of ceftaroline fosamil vs. ceftriaxone, FOCUS 1 and FOCUS 2, enrolled adults with CAP. Only FOCUS 1 included 24-h adjunctive clarithromycin therapy for all patients on day 1. Day 4 and test-of-cure (TOC) outcomes were compared for adjunctive vs. no adjunctive therapy. RESULTS: Of 1240 enrolled patients, 130 patients with CAP due to atypical pathogens alone were included (FOCUS 1, n = 64; FOCUS 2, n = 66). Among patients infected with Mycoplasma pneumoniae and/or Chlamydophila pneumoniae alone, a higher clinical response rate was observed with clarithromycin plus ceftaroline fosamil or ceftriaxone compared with treatment without additional clarithromycin at day 4 [38/49 (77.6%; FOCUS 1) vs. 24/43 (55.8%; FOCUS 2)], but not at the TOC assessment [42/49 (85.7%; FOCUS 1) vs. 41/43 (95.3%; FOCUS 2)]. In patients infected with Legionella pneumophila alone, a higher clinical response rate with adjunctive clarithromycin therapy was observed at the TOC assessment alone [12/12 (100%; FOCUS 1) vs. 14/19 (73.7%; FOCUS 2)]. The unadjusted odds ratio of a favourable clinical response at day 4 with adjunctive clarithromycin vs. no adjunctive clarithromycin was 2.4 (95% confidence interval 1.1-5.1; P = 0.0299) for all pathogens combined. CONCLUSIONS: These results suggest that empirical antibiotic therapy against atypical pathogens may improve early clinical response rate. This hypothesis is best evaluated in a prospective trial.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ijantimicag.2017.01.043" target="_blank" rel="noreferrer noopener">10.1016/j.ijantimicag.2017.01.043</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2017
80 and over
Adult
Aged
Anti-Bacterial Agents/adverse effects/*therapeutic use
Atypical pathogen
Bacterial/*drug therapy
Ceftaroline fosamil
Ceftriaxone/adverse effects/*therapeutic use
Cephalosporins/adverse effects/*therapeutic use
Chlamydial Pneumonia
Chlamydophila pneumoniae
Clinical Trials
Combination/adverse effects/methods
Community-Acquired Infections/*drug therapy
Community-acquired pneumonia
Department of Internal Medicine
Double-Blind Method
Drug Therapy
Eckburg Paul B
Female
File Thomas M Jr
Friedland H David
Humans
International journal of antimicrobial agents
Legionella pneumophila
Llorens Lily
Macrolide
Macrolides/adverse effects/*therapeutic use
Male
Middle Aged
Mycoplasma
Mycoplasma pneumoniae
NEOMED College of Medicine
Phase III as Topic
Pneumonia
Randomized Controlled Trials as Topic
Talbot George H
Time Factors
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.cll.2004.03.003" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.cll.2004.03.003</a>
Pages
531–551
Issue
2
Volume
24
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Evolution of amoxicillin/clavulanate in the treatment of adults with acute bacterial rhinosinusitis and community-acquired pneumonia in response to antimicrobial-resistance patterns.
Publisher
An entity responsible for making the resource available
Clinics in Laboratory Medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-06
Subject
The topic of the resource
Amoxicillin-Potassium Clavulanate Combination/*therapeutic use; Anti-Bacterial Agents/pharmacology; Bacteria/drug effects/isolation & purification; Bacterial; Combination/*therapeutic use; Community-Acquired Infections/drug therapy/microbiology; Drug Resistance; Drug Therapy; Humans; Microbial Sensitivity Tests; Pneumonia/*drug therapy/microbiology; Sinusitis/*drug therapy/microbiology
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Benninger Michael S; Jacobs Michael R
Description
An account of the resource
Current treatment guidelines for community-acquired respiratory tract infections no longer depend solely on the characteristics of the patient and the clinical syndrome, but on those of the offending pathogen, including presence and level of antimicrobial resistance. The most common respiratory tract pathogens known to cause acute bacterial rhinosinusitis (ABRS) and community-acquired pneumonia (CAP) include Streptococcus pneumoniae and Haemophilus influenzae. The prevalence of antimicrobial resistance, especially b-lactum and macrolide resistance, among S pneumoniae and H influenzae has increased dramatically during the past 2 decades, diminishing the activity of many older antimicrobials against resistant organisms. A pharmacokinetically enhanced formulation of amoxicillin/clavulanate has been developed to fulfill the need for an oral b-lactam antimicrobial that achieves a greater time that the serum drug concentration exceeds the minimum inhibitory concentration (T \textgreater MIC) of antimicrobials against pathogens than conventional formulations to improve activity against S pneumoniae with reduced susceptibility to penicillin. The b-lactamase inhibitor clavulanate allows for coverage of b-lactamase-producing pathogens, such as H influenzae and M catarrhalis. This article reviews the rationale for, and evolution of, oral amoxicillin clavulanate for ABRS and CAP
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.cll.2004.03.003" target="_blank" rel="noreferrer noopener">10.1016/j.cll.2004.03.003</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2004
Amoxicillin-Potassium Clavulanate Combination/*therapeutic use
Anti-Bacterial Agents/pharmacology
Bacteria/drug effects/isolation & purification
Bacterial
Benninger Michael S
Clinics in laboratory medicine
Combination/*therapeutic use
Community-Acquired Infections/drug therapy/microbiology
Department of Internal Medicine
Drug Resistance
Drug Therapy
File Thomas M Jr
Humans
Jacobs Michael R
Microbial Sensitivity Tests
NEOMED College of Medicine
Pneumonia/*drug therapy/microbiology
Sinusitis/*drug therapy/microbiology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
30–37
Volume
16 Suppl2
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
[Clinical impact of appropriate use of antibiotic in hospital according to CARAT criteria].
Publisher
An entity responsible for making the resource available
Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive
Date
A point or period of time associated with an event in the lifecycle of the resource
2008
2008-04
Subject
The topic of the resource
Humans; *Practice Guidelines as Topic; Intensive Care Units; Anti-Bacterial Agents/pharmacology/*therapeutic use; Evidence-Based Medicine; Organizational Policy; Europe/epidemiology; Clinical Trials as Topic; *Guideline Adherence; Bacterial Infections/drug therapy/epidemiology; Drug Utilization; Hospitals/*standards; Patients' Rooms; *Drug Resistance; Multiple; Bacterial
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
In response to the overuse and misuse of antibiotics, leading to increasing bacterial resistance and the decreasing development of new antibiotics, the Council for Appropriate and Rational Antibiotic Therapy (an independent, interdisciplinary panel of healthcare professionals established to advocate the appropriate use of antibiotics) has developed criteria to guide proper antibiotic selection. These criteria include: establishment of a need to justify use of antibiotics (e.g., colonization versus disease); evidence-based results; therapeutic benefits; safety; use of pharmacodynamic indices for optimal drug and optimal duration; cost-effectiveness. Promoting the appropriate use of antibiotics should provide for optimal outcomes for our patients.
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Drug Resistance
*Guideline Adherence
*Practice Guidelines as Topic
2008
Anti-Bacterial Agents/pharmacology/*therapeutic use
Bacterial
Bacterial Infections/drug therapy/epidemiology
Clinical Trials as Topic
Department of Internal Medicine
Drug Utilization
Europe/epidemiology
Evidence-Based Medicine
File Thomas M Jr
Hospitals/*standards
Humans
Intensive Care Units
Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive
Multiple
NEOMED College of Medicine
Organizational Policy
Patients' Rooms
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3949/ccjm.80a.13029" target="_blank" rel="noreferrer noopener">http://doi.org/10.3949/ccjm.80a.13029</a>
Pages
619–620
Issue
10
Volume
80
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Another perspective: reducing the overtreatment of pneumonia.
Publisher
An entity responsible for making the resource available
Cleveland Clinic journal of medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2013
2013-10
Subject
The topic of the resource
Humans; Age Factors; *Diagnostic Errors; Comorbidity; Anti-Bacterial Agents/therapeutic use; Pneumonia/*diagnosis/*drug therapy
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3949/ccjm.80a.13029" target="_blank" rel="noreferrer noopener">10.3949/ccjm.80a.13029</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Diagnostic Errors
2013
Age Factors
Anti-Bacterial Agents/therapeutic use
Cleveland Clinic journal of medicine
Comorbidity
Department of Internal Medicine
File Thomas M Jr
Humans
NEOMED College of Medicine
Pneumonia/*diagnosis/*drug therapy
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.3949/ccjm.74.suppl_4.s6" target="_blank" rel="noreferrer noopener">http://doi.org/10.3949/ccjm.74.suppl_4.s6</a>
Pages
S6–11
Volume
74 Suppl 4
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Impact of community-acquired methicillin-resistant Staphylococcus aureus in the hospital setting.
Publisher
An entity responsible for making the resource available
Cleveland Clinic journal of medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2007
2007-08
Subject
The topic of the resource
Humans; Hospitals; Community-Acquired Infections/epidemiology/microbiology/*prevention & control; Cross Infection/epidemiology/microbiology/*prevention & control; Infection Control; Methicillin Resistance/*genetics; Staphylococcal Infections/drug therapy/epidemiology/*prevention & control; Staphylococcus aureus/*drug effects/genetics; DNA; Bacterial
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
The epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) is undergoing a transformation as isolates of this historically health care-associated pathogen are reported with increasing frequency in otherwise healthy community-dwelling individuals. This article provides a brief review of the differences between health care-associated and community-acquired MRSA and discusses the potential impact of the changing epidemiology of MRSA on the hospital setting.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.3949/ccjm.74.suppl_4.s6" target="_blank" rel="noreferrer noopener">10.3949/ccjm.74.suppl_4.s6</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2007
Bacterial
Cleveland Clinic journal of medicine
Community-Acquired Infections/epidemiology/microbiology/*prevention & control
Cross Infection/epidemiology/microbiology/*prevention & control
Department of Internal Medicine
DNA
File Thomas M Jr
Hospitals
Humans
Infection Control
Methicillin Resistance/*genetics
NEOMED College of Medicine
Staphylococcal Infections/drug therapy/epidemiology/*prevention & control
Staphylococcus aureus/*drug effects/genetics
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.2165/00151829-200504001-00007" target="_blank" rel="noreferrer noopener">http://doi.org/10.2165/00151829-200504001-00007</a>
Pages
25–30
Volume
4 Suppl 1
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Solutions to the problem of bacterial resistance.
Publisher
An entity responsible for making the resource available
Treatments in respiratory medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
1905-06
Subject
The topic of the resource
Humans; *Practice Guidelines as Topic; Anti-Bacterial Agents/*therapeutic use; Drug Administration Schedule; Drug Utilization; Drug Prescriptions/standards; Professional Practice/*standards; Unnecessary Procedures; *Drug Resistance; Dose-Response Relationship; Drug; Bacterial
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
The recent increase in bacterial resistance has been, and continues to be, unmatched by drug discovery and development. The judicious use of antibacterials must be observed so as to contain bacterial resistance and maintain the utility of agents currently on the market. Appropriate antibacterial use involves antibacterial avoidance when not indicated. When indicated, appropriate antibacterial use dictates that the optimal drug, dose and duration be utilized. Professional society guidelines facilitate drug selection as well as outline diagnostic criteria and important considerations for patient stratification. Pharmacodynamics is also key for drug selection and often guides determination of not only the optimal drug but also the optimal dose and duration. Importantly, bacterial eradication is essential, as it will reduce clinical failure, recurrence, or relapse and prevent the selection of resistance. Additional strategies to influence antibacterial prescribing and use such as formal continuing medical education, printed educational materials, better diagnostic tests, and vaccination contribute to the efforts to minimize bacterial resistance and are also addressed.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.2165/00151829-200504001-00007" target="_blank" rel="noreferrer noopener">10.2165/00151829-200504001-00007</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Drug Resistance
*Practice Guidelines as Topic
2005
Anti-Bacterial Agents/*therapeutic use
Bacterial
Department of Internal Medicine
Dose-Response Relationship
Drug
Drug Administration Schedule
Drug Prescriptions/standards
Drug Utilization
File Thomas M Jr
Humans
NEOMED College of Medicine
Professional Practice/*standards
Treatments in respiratory medicine
Unnecessary Procedures
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1097/00132980-200506000-00002" target="_blank" rel="noreferrer noopener">http://doi.org/10.1097/00132980-200506000-00002</a>
Pages
123–124
Issue
2
Volume
18
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Community-associated methicillin-resistant Staphylococcus aureas: not only a cause of skin infections, also a new cause of pneumonia.
Publisher
An entity responsible for making the resource available
Current Opinion in Infectious Diseases
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-04
Subject
The topic of the resource
*Methicillin Resistance; Anti-Bacterial Agents/pharmacology; Bacterial/*epidemiology/*microbiology; Community-Acquired Infections; Humans; Pneumonia; Staphylococcal Infections/*epidemiology; Staphylococcus aureus/*drug effects
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1097/00132980-200506000-00002" target="_blank" rel="noreferrer noopener">10.1097/00132980-200506000-00002</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Methicillin Resistance
2005
Anti-Bacterial Agents/pharmacology
Bacterial/*epidemiology/*microbiology
Community-Acquired Infections
Current opinion in infectious diseases
Department of Internal Medicine
File Thomas M Jr
Humans
NEOMED College of Medicine
Pneumonia
Staphylococcal Infections/*epidemiology
Staphylococcus aureus/*drug effects
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1086/653048" target="_blank" rel="noreferrer noopener">http://doi.org/10.1086/653048</a>
Pages
S42–47
Volume
51 Suppl 1
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Recommendations for treatment of hospital-acquired and ventilator-associated pneumonia: review of recent international guidelines.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-08
Subject
The topic of the resource
*Practice Guidelines as Topic; Anti-Bacterial Agents/*therapeutic use; Bacteria/drug effects/isolation & purification; Bacterial/diagnosis/*drug therapy; Clinical Trials as Topic; Cross Infection/diagnosis/*drug therapy; Hospitals; Humans; Microbial Sensitivity Tests; Pneumonia; Time Factors; Ventilator-Associated/diagnosis/*drug therapy
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
Recently published guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia are reviewed for recommendations regarding diagnosis and antimicrobial therapy to assess the implications for development of future clinical trials. Despite some differences (mostly related to likely pathogens), there is a general agreement about the recommended approach to management. All of the reviewed guidelines invariably recommend early, appropriate antimicrobial therapy and avoidance of excessive antimicrobials by deescalation of therapy on the basis of microbiological culture results and the clinical response of the patient. Developers of future clinical trials will need to be mindful of these recommendations to maintain best practice care for each investigator.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1086/653048" target="_blank" rel="noreferrer noopener">10.1086/653048</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Practice Guidelines as Topic
2010
Anti-Bacterial Agents/*therapeutic use
Bacteria/drug effects/isolation & purification
Bacterial/diagnosis/*drug therapy
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Clinical Trials as Topic
Cross Infection/diagnosis/*drug therapy
Department of Internal Medicine
File Thomas M Jr
Hospitals
Humans
Microbial Sensitivity Tests
NEOMED College of Medicine
Pneumonia
Time Factors
Ventilator-Associated/diagnosis/*drug therapy
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1086/421354" target="_blank" rel="noreferrer noopener">http://doi.org/10.1086/421354</a>
Pages
S159–164
Volume
39 Suppl 3
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-09
Subject
The topic of the resource
Anti-Infective Agents/*therapeutic use; Community-Acquired Infections/*drug therapy/microbiology; Humans; Pneumonia/*drug therapy/microbiology; Streptococcus pneumoniae/drug effects/isolation & purification; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
Streptococcus pneumoniae, the most important respiratory tract pathogen implicated in community-acquired pneumonia (CAP), is becoming increasingly resistant in vitro to the beta -lactams and macrolides, and fluoroquinolone resistance has been detected. A growing body of evidence suggests that prolonged antimicrobial use may contribute directly and indirectly to increased antimicrobial resistance among common respiratory pathogens. Long-term exposure to antimicrobial agents, especially less-potent agents, directly increases selection pressure for resistance. Indirectly, poor patient compliance, multiple daily dosing, and the increased risk of adverse events further complicate the resistance issue and diminish the efficacy of long-term antimicrobial use. Controlled clinical trials addressing the appropriate duration of therapy for CAP are lacking. However, available data suggest that with appropriate antibiotic selection, based on appropriate spectrum, potency, and pharmacokinetic/pharmacodynamic profile, lower respiratory tract infections in outpatients can be successfully treated in \textless7 days rather than the 7-14 days currently recommended.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1086/421354" target="_blank" rel="noreferrer noopener">10.1086/421354</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2004
Anti-Infective Agents/*therapeutic use
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Community-Acquired Infections/*drug therapy/microbiology
Department of Internal Medicine
File Thomas M Jr
Humans
NEOMED College of Medicine
Pneumonia/*drug therapy/microbiology
Streptococcus pneumoniae/drug effects/isolation & purification
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1086/324526" target="_blank" rel="noreferrer noopener">http://doi.org/10.1086/324526</a>
Pages
S17–26
Volume
34 Suppl 1
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2002
2002-03
Subject
The topic of the resource
*beta-Lactam Resistance; beta-Lactams/economics/*therapeutic use; Contraindications; Humans; Pneumococcal/*drug therapy/economics/pathology; Pneumonia; Practice Guidelines as Topic; Streptococcus pneumoniae/*drug effects/metabolism
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
The beta-lactam antibiotics (penicillins and cephalosporins) are commonly prescribed for the treatment of community-acquired pneumonia. However, Streptococcus pneumoniae, the most common etiologic agent of community-acquired pneumonia, has become increasingly resistant to beta-lactams over the past decade. The results of several studies suggest that penicillins remain effective for streptococcal pneumonia when the infecting pathogen has a minimal inhibitory concentration (MIC) /=4 microgram/mL, increased rates of mortality (for patients who survive their first 4 days of hospitalization) may occur. Currently, 3.5%-7.8% of S. pneumoniae clinical isolates have MICs that fall in this latter class, but these rates may rise in the future. The clinical relevance of in vitro resistance may be related to at least 3 factors: concordance of antimicrobial therapy, severity of illness, and virulence.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1086/324526" target="_blank" rel="noreferrer noopener">10.1086/324526</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*beta-Lactam Resistance
2002
beta-Lactams/economics/*therapeutic use
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Contraindications
Department of Internal Medicine
File Thomas M Jr
Humans
NEOMED College of Medicine
Pneumococcal/*drug therapy/economics/pathology
Pneumonia
Practice Guidelines as Topic
Streptococcus pneumoniae/*drug effects/metabolism
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s1098-3597(03)90026-3" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s1098-3597(03)90026-3</a>
Pages
S21–28
Volume
Suppl 3
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
A new dosing paradigm: high-dose, short-course fluoroquinolone therapy for community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Clinical Cornerstone
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
1905-6
Subject
The topic of the resource
Community-Acquired Infections/*drug therapy; Fluoroquinolones/*administration & dosage/pharmacology/therapeutic use; Humans; Ofloxacin/administration & dosage/pharmacology/therapeutic use; Pneumococcal/*drug therapy; Pneumonia; Safety; Time Factors; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
The goals of optimal antimicrobial therapy are to treat infection effectively, to improve the clinical condition of the patient, and to prevent the emergence of resistant bacterial strains. For ideal drug usage the World Health Organization recommends administering the correct drug by the best route, in the right amount, at optimum intervals for the appropriate period, and after an accurate diagnosis. This article discusses the use of high-dose, short-course fluoroquinolone therapy as an effective option for patients with community-acquired pneumonia.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s1098-3597(03)90026-3" target="_blank" rel="noreferrer noopener">10.1016/s1098-3597(03)90026-3</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2003
Clinical cornerstone
Community-Acquired Infections/*drug therapy
Department of Internal Medicine
File Thomas M Jr
Fluoroquinolones/*administration & dosage/pharmacology/therapeutic use
Humans
NEOMED College of Medicine
Ofloxacin/administration & dosage/pharmacology/therapeutic use
Pneumococcal/*drug therapy
Pneumonia
Safety
Time Factors
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ijantimicag.2007.07.038" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ijantimicag.2007.07.038</a>
Pages
S131–134
Volume
30 Suppl 2
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults.
Publisher
An entity responsible for making the resource available
International journal of antimicrobial agents
Date
A point or period of time associated with an event in the lifecycle of the resource
2007
2007-12
Subject
The topic of the resource
Adult; Amoxicillin-Potassium Clavulanate Combination/*administration & dosage/pharmacokinetics/therapeutic use; Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/therapeutic use; Bacteria/*drug effects/isolation & purification; Community-Acquired Infections/*drug therapy/microbiology; Humans; Pneumonia/drug therapy/microbiology; Respiratory Tract Infections/*drug therapy/microbiology; Sinusitis/drug therapy/microbiology
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
Rising levels of resistance amongst the major respiratory pathogens have compromised empiric antimicrobial therapy. This, coupled with a recent lack in availability of novel classes of antibacterials, has led to a need for new approaches to combat community respiratory tract infections. Bacteriological and clinical efficacy in two trials involving patients with acute bacterial sinusitis and six trials of patients with community-acquired pneumonia has shown that the development of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate (Augmentin SR, available as Augmentin XR in the USA) has allowed amoxicillin/clavulanate to retain its place in the treatment of respiratory tract infections today.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ijantimicag.2007.07.038" target="_blank" rel="noreferrer noopener">10.1016/j.ijantimicag.2007.07.038</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2007
Adult
Amoxicillin-Potassium Clavulanate Combination/*administration & dosage/pharmacokinetics/therapeutic use
Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/therapeutic use
Bacteria/*drug effects/isolation & purification
Community-Acquired Infections/*drug therapy/microbiology
Department of Internal Medicine
File Thomas M Jr
Humans
International journal of antimicrobial agents
NEOMED College of Medicine
Pneumonia/drug therapy/microbiology
Respiratory Tract Infections/*drug therapy/microbiology
Sinusitis/drug therapy/microbiology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.ccm.2011.05.011" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.ccm.2011.05.011</a>
Pages
417–430
Issue
3
Volume
32
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
New diagnostic tests for pneumonia: what is their role in clinical practice?
Publisher
An entity responsible for making the resource available
Clinics in Chest Medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-09
Subject
The topic of the resource
Antigens; Bacterial/*diagnosis/metabolism; Bacterial/urine; Calcitonin/blood; Community-Acquired Infections/*diagnosis/metabolism/*microbiology/virology; Humans; Nucleic Acid Amplification Techniques; Pneumonia; Polymerase Chain Reaction; Protein Precursors/blood; Viral/*diagnosis/metabolism
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
The utility of diagnostic studies to determine the etiologic agents of community-acquired pneumonia has been controversial in part because of the lack of rapid, accurate, easily performed, and cost-effective methods. Advancements in molecular testing methods and biological markers are becoming available with marked expansion of diagnostic capability for infectious diseases. Subsequent studies and clinical experience will clarify their real clinical value.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.ccm.2011.05.011" target="_blank" rel="noreferrer noopener">10.1016/j.ccm.2011.05.011</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2011
Antigens
Bacterial/*diagnosis/metabolism
Bacterial/urine
Calcitonin/blood
Clinics in chest medicine
Community-Acquired Infections/*diagnosis/metabolism/*microbiology/virology
Department of Internal Medicine
File Thomas M Jr
Humans
NEOMED College of Medicine
Nucleic Acid Amplification Techniques
Pneumonia
Polymerase Chain Reaction
Protein Precursors/blood
Viral/*diagnosis/metabolism
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.amjmed.2010.02.002" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.amjmed.2010.02.002</a>
Pages
S4–15
Issue
4
Volume
123
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Case studies of lower respiratory tract infections: community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
The American journal of medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-04
Subject
The topic of the resource
Acute – Microbiology; Adult; Adult/microbiology; Aged; Anti-Bacterial Agents/*therapeutic use; Antibiotics – Therapeutic Use; Antitubercular Agents – Therapeutic Use; Antitubercular Agents/therapeutic use; Community-Acquired Infections – Diagnosis; Community-Acquired Infections – Drug Therapy; Community-Acquired Infections/diagnosis/drug therapy; Cough; Cough – Microbiology; Cough/microbiology/virology; Diagnosis; Differential; Dyspnea; Fatal Outcome; Female; Fever – Microbiology; Fever/microbiology; Hemoptysis – Microbiology; Hemoptysis/microbiology; Human; Human – Complications; Human – Diagnosis; Human/complications/*diagnosis; Humans; Hypotension – Microbiology; Hypotension/microbiology; Influenza; Leukopenia – Microbiology; Leukopenia/microbiology; Male; Methicillin-Resistant Staphylococcus Aureus; Methicillin-Resistant Staphylococcus aureus/*isolation & purification; Miliary/diagnosis/drug therapy; Multiple Organ Dysfunction Syndrome – Microbiology; Multiple Organ Failure/microbiology; Mycobacterium Tuberculosis; Mycobacterium tuberculosis/isolation & purification; Pneumonia – Diagnosis; Pneumonia – Drug Therapy; Pneumonia – Microbiology; Pneumonia – Therapy; Pneumonia/*diagnosis/*drug therapy/microbiology/therapy; Practice Guidelines; Practice Guidelines as Topic; Respiratory Distress Syndrome; Risk Factors; Severity of Illness Index; Severity of Illness Indices; Smoking; Smoking/adverse effects; Staphylococcal Infections – Diagnosis; Staphylococcal Infections – Drug Therapy; Staphylococcal Infections – Microbiology; Staphylococcal Infections – Therapy; Staphylococcal Infections/*diagnosis/*drug therapy/microbiology/therapy; Tuberculosis; Tuberculosis – Diagnosis; Tuberculosis – Drug Therapy
Creator
An entity primarily responsible for making the resource
File Thomas M Jr
Description
An account of the resource
Community-acquired pneumonia (CAP) is a common and potentially serious illness with significant human and economic costs to society. The recent collaborative statement from the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) represents the most up-to-date evidence-based guidelines from North America, incorporating important advances in the management of patients with CAP. The cases presented in this review highlight many of the recent recommendations from the IDSA/ATS guidelines.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.amjmed.2010.02.002" target="_blank" rel="noreferrer noopener">10.1016/j.amjmed.2010.02.002</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
Acute – Microbiology
Adult
Adult/microbiology
Aged
Anti-Bacterial Agents/*therapeutic use
Antibiotics – Therapeutic Use
Antitubercular Agents – Therapeutic Use
Antitubercular Agents/therapeutic use
Community-Acquired Infections – Diagnosis
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections/diagnosis/drug therapy
Cough
Cough – Microbiology
Cough/microbiology/virology
Department of Internal Medicine
Diagnosis
Differential
Dyspnea
Fatal Outcome
Female
Fever – Microbiology
Fever/microbiology
File Thomas M Jr
Hemoptysis – Microbiology
Hemoptysis/microbiology
Human
Human – Complications
Human – Diagnosis
Human/complications/*diagnosis
Humans
Hypotension – Microbiology
Hypotension/microbiology
Influenza
Leukopenia – Microbiology
Leukopenia/microbiology
Male
Methicillin-Resistant Staphylococcus aureus
Methicillin-Resistant Staphylococcus aureus/*isolation & purification
Miliary/diagnosis/drug therapy
Multiple Organ Dysfunction Syndrome – Microbiology
Multiple Organ Failure/microbiology
Mycobacterium Tuberculosis
Mycobacterium tuberculosis/isolation & purification
NEOMED College of Medicine
Pneumonia – Diagnosis
Pneumonia – Drug Therapy
Pneumonia – Microbiology
Pneumonia – Therapy
Pneumonia/*diagnosis/*drug therapy/microbiology/therapy
Practice Guidelines
Practice Guidelines as Topic
Respiratory Distress Syndrome
Risk Factors
Severity of Illness Index
Severity of Illness Indices
Smoking
Smoking/adverse effects
Staphylococcal Infections – Diagnosis
Staphylococcal Infections – Drug Therapy
Staphylococcal Infections – Microbiology
Staphylococcal Infections – Therapy
Staphylococcal Infections/*diagnosis/*drug therapy/microbiology/therapy
The American journal of medicine
Tuberculosis
Tuberculosis – Diagnosis
Tuberculosis – Drug Therapy
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1001/jama.294.21.2760" target="_blank" rel="noreferrer noopener">http://doi.org/10.1001/jama.294.21.2760</a>
Pages
2760–2763
Issue
21
Volume
294
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Pneumonia in older adults: reversing the trend.
Publisher
An entity responsible for making the resource available
JAMA: Journal of the American Medical Association
Date
A point or period of time associated with an event in the lifecycle of the resource
2005
2005-12-07
Subject
The topic of the resource
Aged; 80 and Over; Pneumonia – Risk Factors; Immunization – Trends; Pneumonia – Epidemiology – In Old Age
Creator
An entity primarily responsible for making the resource
File T M Jr; Tan J S; File Thomas M Jr; Tan James S
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1001/jama.294.21.2760" target="_blank" rel="noreferrer noopener">10.1001/jama.294.21.2760</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2005
80 and over
Aged
Department of Internal Medicine
File T M Jr
File Thomas M Jr
Immunization – Trends
JAMA: Journal of the American Medical Association
NEOMED College of Medicine
Pneumonia – Epidemiology – In Old Age
Pneumonia – Risk Factors
Tan J S
Tan James S